(Reuters) – Merck & Co said on Monday the U.S. Food and Drug Administration declined to approve its experimental drug for the treatment of chronic cough and sought additional information on the treatment’s effectiveness.
Merck said it would meet with the agency to discuss next steps on the oral drug, gefapixant.
(Reporting by Manojna Maddipatla in Bengaluru; Editing by Saumyadeb Chakrabarty)
